Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

Survival and risk factors for progression after resection of the dominant tumor in multifocal, lepidic-type pulmonary adenocarcinoma.

Gao RW, Berry MF, Kunder CA, Khuong AA, Wakelee H, Neal JW, Backhus LM, Shrager JB.

J Thorac Cardiovasc Surg. 2017 Dec;154(6):2092-2099.e2. doi: 10.1016/j.jtcvs.2017.07.034. Epub 2017 Aug 1.

PMID:
28863952
2.

A dominant adenocarcinoma with multifocal ground glass lesions does not behave as advanced disease.

Gu B, Burt BM, Merritt RE, Stephanie S, Nair V, Hoang CD, Shrager JB.

Ann Thorac Surg. 2013 Aug;96(2):411-8. doi: 10.1016/j.athoracsur.2013.04.048. Epub 2013 Jun 24.

PMID:
23806231
3.

Surgical Management of Multifocal Ground-Glass Opacities of the Lung: Correlation of Clinicopathologic and Radiologic Findings.

Hattori A, Matsunaga T, Takamochi K, Oh S, Suzuki K.

Thorac Cardiovasc Surg. 2017 Mar;65(2):142-149. doi: 10.1055/s-0036-1572437. Epub 2016 Feb 22.

PMID:
26902328
4.

Long-term results after surgical treatment of the dominant lung adenocarcinoma associated with ground-glass opacities.

Bongiolatti S, Corzani R, Borgianni S, Meniconi F, Cipollini F, Gonfiotti A, Viggiano D, Paladini P, Voltolini L.

J Thorac Dis. 2018 Aug;10(8):4838-4848. doi: 10.21037/jtd.2018.07.21.

5.

Natural History of Ground-Glass Lesions Among Patients With Previous Lung Cancer.

Shewale JB, Nelson DB, Rice DC, Sepesi B, Hofstetter WL, Mehran RJ, Vaporciyan AA, Walsh GL, Swisher SG, Roth JA, Antonoff MB.

Ann Thorac Surg. 2018 Jun;105(6):1671-1677. doi: 10.1016/j.athoracsur.2018.01.031. Epub 2018 Feb 9.

PMID:
29432718
6.
7.

Survival of a surgical series of lung cancer patients with synchronous multiple ground-glass opacities, and the management of their residual lesions.

Shimada Y, Saji H, Otani K, Maehara S, Maeda J, Yoshida K, Kato Y, Hagiwara M, Kakihana M, Kajiwara N, Ohira T, Akata S, Ikeda N.

Lung Cancer. 2015 May;88(2):174-80. doi: 10.1016/j.lungcan.2015.02.016. Epub 2015 Mar 1.

PMID:
25758554
8.

Management of ground-glass opacities: should all pulmonary lesions with ground-glass opacity be surgically resected?

Kobayashi Y, Mitsudomi T.

Transl Lung Cancer Res. 2013 Oct;2(5):354-63. doi: 10.3978/j.issn.2218-6751.2013.09.03. Review.

9.

Ground-Glass Opacity Is a Strong Prognosticator for Pathologic Stage IA Lung Adenocarcinoma.

Miyoshi T, Aokage K, Katsumata S, Tane K, Ishii G, Tsuboi M.

Ann Thorac Surg. 2019 Jul;108(1):249-255. doi: 10.1016/j.athoracsur.2019.01.079. Epub 2019 Mar 12.

PMID:
30876742
10.

Does ground glass opacity-dominant feature have a prognostic significance even in clinical T2aN0M0 lung adenocarcinoma?

Nakamura S, Fukui T, Kawaguchi K, Fukumoto K, Hirakawa A, Yokoi K.

Lung Cancer. 2015 Jul;89(1):38-42. doi: 10.1016/j.lungcan.2015.04.011. Epub 2015 Apr 28.

PMID:
25963638
11.

The prognosis of invasive adenocarcinoma presenting as ground-glass opacity on chest computed tomography after sublobar resection.

Moon Y, Lee KY, Park JK.

J Thorac Dis. 2017 Oct;9(10):3782-3792. doi: 10.21037/jtd.2017.09.40.

12.

Focal ground-glass opacities in non-small cell lung carcinoma resection patients.

Koo CW, Miller WT, Kucharczuk JC.

Eur J Radiol. 2012 Jan;81(1):139-45. doi: 10.1016/j.ejrad.2010.07.001. Epub 2010 Jul 31.

PMID:
20674206
13.

Whack-a-mole strategy for multifocal ground glass opacities of the lung.

Suzuki K.

J Thorac Dis. 2017 Apr;9(Suppl 3):S201-S207. doi: 10.21037/jtd.2017.04.03. Review.

14.

Appropriate sublobar resection choice for ground glass opacity-dominant clinical stage IA lung adenocarcinoma: wedge resection or segmentectomy.

Tsutani Y, Miyata Y, Nakayama H, Okumura S, Adachi S, Yoshimura M, Okada M.

Chest. 2014 Jan;145(1):66-71. doi: 10.1378/chest.13-1094.

PMID:
24551879
15.

Pulmonary ground-glass opacity (GGO) lesions-large size and a history of lung cancer are risk factors for growth.

Hiramatsu M, Inagaki T, Inagaki T, Matsui Y, Satoh Y, Okumura S, Ishikawa Y, Miyaoka E, Nakagawa K.

J Thorac Oncol. 2008 Nov;3(11):1245-50. doi: 10.1097/JTO.0b013e318189f526.

16.

Management of multiple pure ground-glass opacity lesions in patients with bronchioloalveolar carcinoma.

Kim HK, Choi YS, Kim J, Shim YM, Lee KS, Kim K.

J Thorac Oncol. 2010 Feb;5(2):206-10. doi: 10.1097/JTO.0b013e3181c422be.

17.

The long-term course of ground-glass opacities detected on thin-section computed tomography.

Lee SW, Leem CS, Kim TJ, Lee KW, Chung JH, Jheon S, Lee JH, Lee CT.

Respir Med. 2013 Jun;107(6):904-10. doi: 10.1016/j.rmed.2013.02.014. Epub 2013 Mar 17.

18.

Bronchioloalveolar carcinoma and adenocarcinoma with bronchioloalveolar features presenting as ground-glass opacities on CT.

Mirtcheva RM, Vazquez M, Yankelevitz DF, Henschke CI.

Clin Imaging. 2002 Mar-Apr;26(2):95-100. Review.

PMID:
11852215
19.

Surgical outcomes in lung cancer presenting as ground-glass opacities of 3 cm or less: a review of 5 years' experience.

Duann CW, Hung JJ, Hsu PK, Huang CS, Hsieh CC, Hsu HS, Wu YC, Hsu WH.

J Chin Med Assoc. 2013 Dec;76(12):693-7. doi: 10.1016/j.jcma.2013.08.005. Epub 2013 Oct 4.

20.

CT-guided Hookwire localization before video-assisted thoracoscopic surgery for solitary ground-glass opacity dominant pulmonary nodules: radiologic-pathologic analysis.

Huang HZ, Wang GZ, Xu LC, Li GD, Wang Y, Wang YH, He XH, Li WT.

Oncotarget. 2017 Nov 20;8(64):108118-108129. doi: 10.18632/oncotarget.22551. eCollection 2017 Dec 8.

Supplemental Content

Support Center